J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial is for men with advanced prostate cancer that may have spread to other
parts of the body.
Currently, once prostate cancer cells have spread from the prostate to other organs it is not
treatable by surgery. The purpose of this study is to treat patients with an experimental
antibody (i.e. that has not been FDA approved) called J591 that attaches itself to a special
protein on cancer cells called PSMA to try to eliminate these cancer cells (called
circulating tumor cells) from the circulation.
In the initial phase of the study, 6 participants will receive the experimental J591
treatment. Routine blood tests, research blood tests, physical exam will be performed at each
visit. Participants will also be asked to complete a questionnaire about how they are
feeling. Participants will have a radiographic scan every 3 months to check the status of
their disease.
Participants who tolerate the treatment well may be re-treated at the same level every 3
months, and may continue on treatment as long as they are responding to therapy and not
experiencing unacceptable side effects.